Zura Bio (ZURA) Competitors $2.55 +0.05 (+2.00%) (As of 05:27 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ZURA vs. STOK, ABUS, PHVS, ORIC, AUTL, HUMA, VECT, ANNX, ALT, and DNAShould you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Stoke Therapeutics (STOK), Arbutus Biopharma (ABUS), Pharvaris (PHVS), ORIC Pharmaceuticals (ORIC), Autolus Therapeutics (AUTL), Humacyte (HUMA), VectivBio (VECT), Annexon (ANNX), Altimmune (ALT), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Zura Bio vs. Stoke Therapeutics Arbutus Biopharma Pharvaris ORIC Pharmaceuticals Autolus Therapeutics Humacyte VectivBio Annexon Altimmune Ginkgo Bioworks Stoke Therapeutics (NASDAQ:STOK) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking. Does the media refer more to STOK or ZURA? In the previous week, Zura Bio had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 5 mentions for Zura Bio and 3 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.67 beat Zura Bio's score of 0.17 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor STOK or ZURA? Stoke Therapeutics received 91 more outperform votes than Zura Bio when rated by MarketBeat users. However, 79.17% of users gave Zura Bio an outperform vote while only 74.83% of users gave Stoke Therapeutics an outperform vote. CompanyUnderperformOutperformStoke TherapeuticsOutperform Votes11074.83% Underperform Votes3725.17% Zura BioOutperform Votes1979.17% Underperform Votes520.83% Which has more risk and volatility, STOK or ZURA? Stoke Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Do analysts recommend STOK or ZURA? Stoke Therapeutics presently has a consensus target price of $21.29, indicating a potential upside of 97.64%. Zura Bio has a consensus target price of $15.80, indicating a potential upside of 544.90%. Given Zura Bio's higher possible upside, analysts plainly believe Zura Bio is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Zura Bio 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in STOK or ZURA? 61.1% of Zura Bio shares are held by institutional investors. 11.3% of Stoke Therapeutics shares are held by company insiders. Comparatively, 22.1% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings & valuation, STOK or ZURA? Zura Bio has lower revenue, but higher earnings than Stoke Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$16.74M34.07-$104.70M-$2.10-5.13Zura BioN/AN/A-$69.24MN/AN/A Is STOK or ZURA more profitable? Zura Bio has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -629.90%. Zura Bio's return on equity of -37.36% beat Stoke Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics-629.90% -54.45% -40.77% Zura Bio N/A -37.36%-29.81% SummaryZura Bio beats Stoke Therapeutics on 9 of the 14 factors compared between the two stocks. Ad StocksToTradeTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…Click here to review Tim’s special Holiday offer before it’s too late. Get Zura Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZURA vs. The Competition Export to ExcelMetricZura BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$159.96M$2.94B$5.17B$9.03BDividend YieldN/A1.89%4.96%4.20%P/E RatioN/A45.4687.1417.05Price / SalesN/A397.961,125.75118.75Price / CashN/A174.7443.2737.84Price / Book1.323.954.824.94Net Income-$69.24M-$42.00M$120.07M$225.13M7 Day Performance2.94%0.38%1.02%3.71%1 Month Performance-19.67%-5.35%16.06%2.47%1 Year Performance-47.54%13.02%28.43%17.10% Zura Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZURAZura Bio3.498 of 5 stars$2.55+2.0%$15.80+519.6%-46.5%$166.49MN/A0.003High Trading VolumeSTOKStoke Therapeutics4.0681 of 5 stars$11.52-1.4%$21.29+84.8%+110.3%$610.18M$16.74M-5.49100ABUSArbutus Biopharma2.6348 of 5 stars$3.18-0.9%$5.50+73.0%+28.4%$602.59M$6.74M-7.4073Positive NewsPHVSPharvaris2.811 of 5 stars$18.92-3.3%$39.25+107.5%-30.7%$602.41MN/A-6.7630Short Interest ↓News CoverageORICORIC Pharmaceuticals3.7992 of 5 stars$8.30+1.1%$18.29+120.3%-10.3%$585.71MN/A-4.6180AUTLAutolus Therapeutics3.0057 of 5 stars$2.20-3.9%$10.40+372.7%-64.9%$585.41M$10.09M-1.82330Short Interest ↑News CoverageHUMAHumacyte3.5745 of 5 stars$4.60-0.9%$13.71+198.1%+93.7%$578.95M$1.57M-3.43150Gap UpHigh Trading VolumeVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030ANNXAnnexon2.5113 of 5 stars$5.25+0.4%$15.80+201.0%+14.3%$559.62MN/A-5.0060ALTAltimmune2.1828 of 5 stars$7.72-6.4%$20.00+159.1%-31.8%$549.09M$52,000.00-4.9850DNAGinkgo Bioworks0.7644 of 5 stars$9.33-7.4%$4.58-51.0%N/A$536.28M$217.11M-0.711,218Gap Down Related Companies and Tools Related Companies STOK Alternatives ABUS Alternatives PHVS Alternatives ORIC Alternatives AUTL Alternatives HUMA Alternatives VECT Alternatives ANNX Alternatives ALT Alternatives DNA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZURA) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zura Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
